IBIO

iBio, Inc. (IBIO) | Rumor.io

iBio

IBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,620

Bullish sentiment (50-day avg)92%

Price to earnings ratio0.59

Market capitalization58.1M

Earnings per share-0.32

Dividend yield (TTM)—

Revenue (annual)100K

Net income (annual)-33M

Social

What share of all stock conversation is about IBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 1

iBio, Inc. ($IBIO) announced preclinical data from an obese non-human primate (NHP) study evaluating IBIO-610, a potentially first-in-class Activin E antibody candidate.
A single dose of IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks in the study, supporting a differentiated, long-acting antibody approach.
The treatment also showed a 73% lean mass preservation compared to semaglutide alone, with full dataset expected at EASD in October 2026.

Generated by AI

Sentiment

Of the messages about IBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	85.71% -14.29	88.86% +1.69
Bearish	—	—	14.29% +14.29	11.14% -1.69

Bullish· Jan 12

$IBIO has a target price of $3.60, with a $26M private placement expected on Jan 13, potentially leading to a 10-20% increase.
IBIO-610 is expected to be a major catalyst, with pre-clin/clin data and an IND filing in 2026, as well as new partner deals and Q2 earnings in Feb.
$IBIO has broken resistance and is expected to reach $3, with a slow squeeze setup and grinding higher above moving averages, positioning for further growth.

Bearish· Dec 10

The company's stock price may be manipulated, with a "nice little head fake" at the open.
The stock has a high short interest, with 1.9 million shorts, making it a potential target for a squeeze.
The stock's price may be driven by speculation and not by fundamental value, with some calling it a "low-priced biotech lottery".

Generated by AI

Topics

Of the messages about IBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	26.67%	7.38%
Technical Analysis	—	0%	28.33%	39.35%
Analysts	—	0%	16.67%	11.9%
Macro	—	0%	28.33%	41.33%
Controversies	—	0%	0%	0.04%
Earnings	—	0%	0%	0%

Announcements· Oct 30

iBio, Inc. (IBIO) announced new preclinical data from an obese non-human primate study evaluating IBIO-610, an Activin E antibody candidate with strong therapeutic potential for obesity.
The data showed an extended half-life of 33.2 days for IBIO-610 in non-human primates, potentially extending to 100 days in humans, which could reduce dosing frequency and improve treatment outcomes.
IBIO-610 demonstrated significant fat-mass reduction and prevention of weight regain in mice, and is now advancing to non-human primate studies as it moves toward clinical development.

Controversies· Oct 13

Johnson & Johnson has paused its COVID-19 vaccine trial due to an unexplained illness in a participant.
The trial is on hold, and Johnson & Johnson may be delayed in the vaccine development process.
The pause in the trial may impact Johnson & Johnson's competitiveness in the vaccine market.

Technical Analysis· Oct 23

iBio Inc (IBIO) is expected to reach $2.684 by Oct 23, 2025, according to a technical analysis roadmap.
The stock is likely to break out soon, with a target of $1.72 and a pullback to $1.57, driven by $50 million in new funding, GLP-1 momentum, and upcoming data release.
The price is retesting the breakout point at $1.30-40 range, with a realistic near-term price target of $2.50-3.00.

Generated by AI

Community

Of the messages about IBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	33.33%	29.63%	51.14%
Newcomers	—	66.67%	70.37%	48.86%

Regulars· Oct 30

The company iBio, Inc. (IBIO) has announced promising preclinical data for its IBIO-610 antibody, showing an extended half-life of 33.2 days in non-human primates, potentially extending to 100 days in humans.
The extended half-life of IBIO-610 could lead to a reduced dosing frequency for the treatment, from twice a week to twice a year, making it a promising candidate for obesity and weight management.
The new data suggests that IBIO-610 has a strong therapeutic potential for fat-selective weight-loss and weight maintenance, with a demonstrated mechanism in mice, and a potential for twice-yearly dosing, which could be a significant advantage over existing treatments.

Newcomers· Jan 6

New investors are excited about iBio, Inc.'s recent gains, with one user reaching their target profit and another expecting a potential second round of gains.
Some newcomers are optimistic about iBio's anti-ActE mAb, with one user expressing enthusiasm and another highlighting the potential for nice gaps in the stock's chart.
iBio's volatility and recent price movements have caught the attention of new investors, with one user warning of a potential decline and another highlighting the stock's potential for a breakout.

Generated by AI

News

iBio stock initiated at buy by H.C. Wainwright with $7 target

13d agoInvesting.com

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

13d agoBenzinga

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursda

13d agoBenzinga

12 Health Care Stocks Moving In Monday's After-Market Session - Circle8 Group (NASDAQ:CIRC), Eocene (NASD

Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose 10.65% to

15d agoBenzinga

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

28d agoYahoo Finance

iBio reports $33 million loss for fiscal 2026, advances pipeline

1mo agoInvesting.com

Also Discussed

Investors talking about IBIO also mention

#	Name	Attention
1	Co-Diagnostics Inc.CODX	0%+0
2	Aytu BioPharma, Inc.AYTU	0%0
3	GHSI - Guardion Health Sciences, Inc.	——
4	VXRT - Vaxart, Inc.	——
5	Inovio Pharmaceuticals Inc.INO	0%+0
6	China Pharma Holdings, Inc.CPHI	0%new
7	Lakeland Industries, Inc.LAKE	0%0
8	TTNP - Titan Pharmaceuticals, Inc.	——
9	VBIV - VBI Vaccines Inc.	——
10	Remark Holdings Inc.MARK	0%0

iBio, Inc.

Healthcare
Biotechnology

iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets. Its current technology stack includes platforms designed for antibody engineering, masking, optimization, and epitope steering, which support preclinical research and early-stage pipeline development. iBio’s work is centered on improving the speed and precision of drug discovery for complex diseases, with an emphasis on antibody-based therapies and related biopharmaceutical programs. Founded in 2008 and headquartered in San Diego, California, iBio plays a niche role in the biotechnology market as a research-driven company advancing AI-enabled biologic discovery.

Website

Location

11750 Sorrento Valley Road

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about IBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 1

iBio, Inc. ($IBIO) announced preclinical data from an obese non-human primate (NHP) study evaluating IBIO-610, a potentially first-in-class Activin E antibody candidate.
A single dose of IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks in the study, supporting a differentiated, long-acting antibody approach.
The treatment also showed a 73% lean mass preservation compared to semaglutide alone, with full dataset expected at EASD in October 2026.

Generated by AI

Sentiment

Of the messages about IBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	85.71% -14.29	88.86% +1.69
Bearish	—	—	14.29% +14.29	11.14% -1.69

Bullish· Jan 12

$IBIO has a target price of $3.60, with a $26M private placement expected on Jan 13, potentially leading to a 10-20% increase.
IBIO-610 is expected to be a major catalyst, with pre-clin/clin data and an IND filing in 2026, as well as new partner deals and Q2 earnings in Feb.
$IBIO has broken resistance and is expected to reach $3, with a slow squeeze setup and grinding higher above moving averages, positioning for further growth.

Bearish· Dec 10

The company's stock price may be manipulated, with a "nice little head fake" at the open.
The stock has a high short interest, with 1.9 million shorts, making it a potential target for a squeeze.
The stock's price may be driven by speculation and not by fundamental value, with some calling it a "low-priced biotech lottery".

Generated by AI

Topics

Of the messages about IBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	26.67%	7.38%
Technical Analysis	—	0%	28.33%	39.35%
Analysts	—	0%	16.67%	11.9%
Macro	—	0%	28.33%	41.33%
Controversies	—	0%	0%	0.04%
Earnings	—	0%	0%	0%

Announcements· Oct 30

iBio, Inc. (IBIO) announced new preclinical data from an obese non-human primate study evaluating IBIO-610, an Activin E antibody candidate with strong therapeutic potential for obesity.
The data showed an extended half-life of 33.2 days for IBIO-610 in non-human primates, potentially extending to 100 days in humans, which could reduce dosing frequency and improve treatment outcomes.
IBIO-610 demonstrated significant fat-mass reduction and prevention of weight regain in mice, and is now advancing to non-human primate studies as it moves toward clinical development.

Controversies· Oct 13

Johnson & Johnson has paused its COVID-19 vaccine trial due to an unexplained illness in a participant.
The trial is on hold, and Johnson & Johnson may be delayed in the vaccine development process.
The pause in the trial may impact Johnson & Johnson's competitiveness in the vaccine market.

Technical Analysis· Oct 23

iBio Inc (IBIO) is expected to reach $2.684 by Oct 23, 2025, according to a technical analysis roadmap.
The stock is likely to break out soon, with a target of $1.72 and a pullback to $1.57, driven by $50 million in new funding, GLP-1 momentum, and upcoming data release.
The price is retesting the breakout point at $1.30-40 range, with a realistic near-term price target of $2.50-3.00.

Generated by AI

Community

Of the messages about IBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	33.33%	29.63%	51.14%
Newcomers	—	66.67%	70.37%	48.86%

Regulars· Oct 30

The company iBio, Inc. (IBIO) has announced promising preclinical data for its IBIO-610 antibody, showing an extended half-life of 33.2 days in non-human primates, potentially extending to 100 days in humans.
The extended half-life of IBIO-610 could lead to a reduced dosing frequency for the treatment, from twice a week to twice a year, making it a promising candidate for obesity and weight management.
The new data suggests that IBIO-610 has a strong therapeutic potential for fat-selective weight-loss and weight maintenance, with a demonstrated mechanism in mice, and a potential for twice-yearly dosing, which could be a significant advantage over existing treatments.

Newcomers· Jan 6

New investors are excited about iBio, Inc.'s recent gains, with one user reaching their target profit and another expecting a potential second round of gains.
Some newcomers are optimistic about iBio's anti-ActE mAb, with one user expressing enthusiasm and another highlighting the potential for nice gaps in the stock's chart.
iBio's volatility and recent price movements have caught the attention of new investors, with one user warning of a potential decline and another highlighting the stock's potential for a breakout.

Generated by AI

iBio

Social

Jul 1

Bullish· Jan 12

Bearish· Dec 10

Announcements· Oct 30

Controversies· Oct 13

Technical Analysis· Oct 23

Regulars· Oct 30

Newcomers· Jan 6

iBio stock initiated at buy by H.C. Wainwright with $7 target

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursda

12 Health Care Stocks Moving In Monday's After-Market Session - Circle8 Group (NASDAQ:CIRC), Eocene (NASD

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

iBio reports $33 million loss for fiscal 2026, advances pipeline

Also Discussed

iBio, Inc.

Company Information

Location

iBio stock initiated at buy by H.C. Wainwright with $7 target

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursda

12 Health Care Stocks Moving In Monday's After-Market Session - Circle8 Group (NASDAQ:CIRC), Eocene (NASD

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

iBio reports $33 million loss for fiscal 2026, advances pipeline

Also Discussed

Social

Jul 1

Bullish· Jan 12

Bearish· Dec 10

Announcements· Oct 30

Controversies· Oct 13

Technical Analysis· Oct 23

Regulars· Oct 30

Newcomers· Jan 6